| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.0072 | 0.9 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.9 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.0094 | 0.9 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |